A Phase II Study of PTK787/ZK222584 (NSC 719335) in Patients With Unresectable Malignant Mesothelioma.

Trial Profile

A Phase II Study of PTK787/ZK222584 (NSC 719335) in Patients With Unresectable Malignant Mesothelioma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2016

At a glance

  • Drugs Vatalanib (Primary)
  • Indications Mesothelioma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Jul 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov. (NCT00898547).
    • 31 Jul 2015 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov. (NCT00898547).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top